Abstract
The "TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia" (TOPIC) trial was stopped preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly due to a strong patient preference for either of the two treatment modalities. This prompted us to initiate a new study on the same subject, with a non-randomized, open-label design: the 'TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC)-3' study.
Original language | English |
---|---|
Article number | 110 |
Number of pages | 2 |
Journal | BMC Cancer |
Volume | 17 |
DOIs | |
Publication status | Published - 7 Feb 2017 |
Keywords
- Cervical intraepithelial neoplasia
- Imiquimod
- Biological markers
- Human papillomavirus
- Natural history